

## **Technology Advisory Committee B Interests Register Topic [ID3971]**

Publication Date: 21/06/2023


Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Dr Warren Linley	TAC Member	Direct financial	AstraZeneca is listed as a potential comparator company and he is currently engaged in a paid project with AstraZeneca in the area of mCRPC.	17/02/2023		It was agreed that his declaration would prevent Dr Linley from participating in discussions on this appraisal.
Stephen Allen	Patient expert	Financial	His nominating organisation, Tackle Prostate Cancer, have received income from the pharmaceutical industry.	09/03/2023		It was agreed that his declaration would not prevent Stephen from providing expert advice to the committee.
Amit Bahl	Clinical expert	Professional and financial interests	He has received meeting support and honoraria payments for educational meetings and advisory boards from Bayer, Astellas, Janssen, Novartis, EUSA, BMS, Pfizer and AAA. He also declared research grants to Institution	12/09/2022 09/03/2023		It was agreed that his declaration would not prevent Amit from providing expert advice to the committee.



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			from Sanofi, Janssen and			
			Bayer.			
Dr Simon	Clinical	Professional	Guy's Cancer Academy (for	12/09/2022		It was agreed that his
Hughes	expert	and	which he is the lead) received			declaration would not
		financial	an unrestricted grant from			prevent Dr Hughes
			Bayer PLC to develop an			from providing expert
			open access online e-learning			advice to the
			course (CPD accredited) on			committee.
			the management of non-			
			metastatic Castration			
			Resistant Prostate Cancer			
			(Bayer had no input regarding			
			the content); He chaired an			
			Advisory Board for Bayer PLC			
			concerning the ARASENS trial			
			and received an honorarium			
			for this; He is a mentor on the			
			Bayer "Future Leaders in			
			Oncology" programme for			
			which he receives an			
			honorarium; He co-Chairs and			
			co-organises the Annual			
			PROSPECT meeting (a UK			
I			multidisciplinary prostate			



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			cancer meeting funded by			
			Astellas) for which he receives			
			an honorarium; He has also			
			received honoraria from			
			Astellas for delivering a			
			webinar to Astellas Europe			
			staff on managing the side			
			effects of androgen			
			deprivation and delivering a			
			series of webinars on the			
			management of bone health			
			in patients on androgen			
			deprivation; Guy's Cancer			
			Academy received an			
			unrestricted grant from			
			Astellas to develop a credit			
			bearing course (at Kings			
			College London) on prostate			
			cancer for advanced non-			
			medical practitioners; Guy's			
			Cancer Academy have just			
			signed a contract with			
			Janssen Brazil to run a 2-day			
			preceptorship for visiting			



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			oncologists from Brazil to cover the whole spectrum of prostate cancer management (and are also exploring a similar model with their European team); He receives honoraria from AstraZeneca to advise on their PARP inhibitor research programme, and their clinician education programme around PARPi.			
Peter Wheatley- Price	TAC Member	Financial	His employer, Takeda, manufacture Leuprorelin (Prostap), an LHRH agonist used in hormone sensitive stages of prostate cancer.	17/02/2023		It was agreed that his declaration would not prevent Peter from participating in discussions on this appraisal.

## **GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER**

**Relevant dates:** Detail here the date the interest arose and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.